Refractive and Biometric Outcomes Following a Single Dose Intravitreal Bevacizumab Administration To evaluate the effect of intravitreal bevacizumab monotherapy on refractive and biometric parameters.
Journal of Ophthalmic and Optometric Sciences,
Vol. 3 No. 2 (2019),
6 April 2019
,
Page 16-20
https://doi.org/10.22037/joos.v3i2.32759
Abstract
Purpose: To evaluate the effect of intravitreal bevacizumab monotherapy on refractive and biometric parameters among patients with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO) or clinically significant macular edema (CSME).
Patients and Methods: This prospective study included patients aged between 35-50 years who received a single dose intravitreal injection of bevacizumab in Khatam-Al-Anbia eye hospital, Mashhad University of Medical Sciences, Mashhad, Iran, from 2015 to 2017. Dry and cycloplegic refraction, visual function, accommodative amplitude, keratometry results, axial length, anterior chamber depth, lens thickness, vitreous length and central corneal thickness, before and 1 and 3 months after injection were evaluated and compared.
Results: Twenty seven patients (fifteen females and twelve males) entered the study with the mean age of 45.18 ± 2.68 years. The mean best corrected visual acuity (BCVA) of patients improved significantly (P = 0.006) three months post injection compared to before injection. No statistically significant difference was observed between the refractive parameters (dry and cycloplegic refraction), accommodative amplitude, biometric parameters including keratometry, axial length, and lens thickness, before and 1 or 3 months after injection.
Conclusion: Based on our findings bevacizumab monotherapy improved the mean BCVA among patients with CRVO, BRVO, or CSME, but had no significant effect on refractive and biometric parameters of the treated eyes up to 3 months after injection.
- Bevacizumab
- Refractive
- Biometry
- keratometry,
How to Cite
References
Holz FG, Pauleikhoff D, Klein R, Bird AC. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol. 2004;137(3):504-10.
Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120(3):338-46.
Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-16.
Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina. 2005;25(7):815-27.
van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005;293(12):1509-13.
Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-72.
Moisseiev E, Loewenstein A. Diabetic Macular Edema: Emerging Strategies and Treatment Algorithms. Dev Ophthalmol. 2017;60:165-74.
Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina. 2006;26(9):994-8.
Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol. 2009;20(3):166-74.
Jonas JB, Libondi T, Golubkina L, Spandau UH, Schlichtenbrede F, Rensch F. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration. Acta Ophthalmol. 2010;88(6):630-4.
Axer-Siegel R, Herscovici Z, Hasanreisoglu M, Kremer I, Benjamini Y, Snir M. Effect of intravitreal bevacizumab (avastin) on the growing rabbit eye. Curr Eye Res. 2009;34(8):660-5.
Chatziralli I, Chatzipantelis A, Dimitriou E, Mpourouki E, Theodossiadis G, Theodossiadis P. Refractive changes after intravitreal ranibizumab injections for diabetic macular oedema. Clin Exp Optom. 2018;101(3):397-9.
Deák GG, Lammer J, Prager S, Mylonas G, Bolz M, Schmidt-Erfurth U, et al. Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology. 2014;121(5):1054-8.
- Abstract Viewed: 177 times
- pdf Downloaded: 85 times
